戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ce, ablation of Pml largely reduces IFNalpha angiostatic ability in Matrigel plug assays.
2  tumor growth in vivo and suggest that these angiostatic activities may one day be exploited to comba
3  that the WARS mutation could potentiate the angiostatic activities of TrpRS by enhancing its interac
4 ynthetase (T2-TrpRS) has demonstrated potent angiostatic activity during retinal developmental neovas
5                                          The angiostatic activity is dose-dependent in both systems.
6 ls may also use this receptor to mediate the angiostatic activity of IP-10/CXCL10, which is also expr
7                                To assess the angiostatic activity of T2-TrpRS, mice were injected int
8 ne, providing a possible explanation for the angiostatic activity of the peptide.
9 ran sulfate proteoglycan perlecan, possesses angiostatic activity via dual receptor antagonism, throu
10  IFNalpha-inducible effector, possess potent angiostatic activity, doing so in part by forming a posi
11                 T2-TrpRS demonstrated potent angiostatic activity, reducing the appearance of patholo
12  the alpha2beta1 integrin and VEGFR2 for its angiostatic activity.
13 llin, the C-terminal module of perlecan, has angiostatic activity.
14 s in aberrant IFNalpha signaling and altered angiostatic activity.
15 ran sulfate proteoglycan perlecan, possesses angiostatic activity.
16 ot been shown to bind CXCR3 receptor or have angiostatic activity.
17         This study examined the effect of an angiostatic agent on the growth of a highly vascularized
18            Calix[4]arene compound 0118 is an angiostatic agent that inhibits tumor growth in mice.
19 r treatment with anecortave acetate, a known angiostatic agent.
20 s was observed after treatment with a single angiostatic agent.
21 indings establish FBLN-3 and FBLN-5 as novel angiostatic agents capable of reducing tumor angiogenesi
22  of one of a variety of anti-inflammatory or angiostatic agents.
23  of thrombospondin-1 and TIMP3, two powerful angiostatic agents.
24 118 is a topomimetic of galectin-1-targeting angiostatic amphipathic peptide Anginex, we had yet to p
25 e characterized by up- and downregulation of angiostatic and angiogenic genes.
26                  The results identify direct angiostatic and antifibrotic effects of the Cxcr3 ligand
27 tained-release devices facilitate high local angiostatic and antipermeability concentrations while mi
28 , however, investigators have focused on the angiostatic and antipermeability properties of corticost
29 uently, miR-21 inhibition in TAMs induced an angiostatic and immunostimulatory activation with potent
30 erived factor (PEDF) is a 50-kD protein with angiostatic and neurotrophic activities that regulates v
31                                     Both new angiostatic and traditional corticosteroids are currentl
32 accination-induced antisera displayed strong angiostatic and tumor-growth-inhibiting properties in a
33 ry genes; 3) late upregulated (days 7 to 14)-angiostatic, anti-inflammatory, and extracellular matrix
34 o suggest a heretofore unrecognized role for angiostatic basement membrane fragments in platelet biol
35 d on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have
36                            Endorepellin, the angiostatic C-terminal domain of the heparan sulfate pro
37 r fibrosis by therapeutic treatment with the angiostatic chemokine Cxcl9 was systematically analyzed
38 mokines such as interleukin 8 (IL-8) and for angiostatic chemokines such as interferon-inducible prot
39                     IP-10 and MIG are potent angiostatic chemokines that may contribute to lung injur
40 ed a significant secretion of angiogenic and angiostatic chemokines, mainly across the hfRPE apical m
41                           Despite this, the 'angiostatic' chemokines inhibited the chemotactic respon
42 ncentrations (100-500 ng/ml) of each of the 'angiostatic' chemokines IP-10, ITAC, and MIG.
43 dent in part on a relative deficiency of the angiostatic CXC chemokine, IFN-gamma-inducible protein-1
44           These results demonstrate that the angiostatic CXC chemokine, IP-10, inhibits fibroplasia a
45  of liver scarring, but a functional role of angiostatic CXCR3 chemokines in this process is unclear.
46          Among inflammatory, angiogenic, and angiostatic cytokines and chemokines, only vascular endo
47                                          The angiostatic effect occurred despite high levels of vascu
48                                          The angiostatic effect of AxCAIL-13 was associated with down
49 t a promising new strategy to potentiate the angiostatic effect of endorepellin and perhaps other ang
50 her define the sequences responsible for the angiostatic effect of TSP-1, we used synthetic peptides.
51 ays markedly suppressed vessel sprouting, an angiostatic effect that was rescued by blocking PERK kin
52 tance against HTLV-induced tumors through an angiostatic effect.
53 serpine compensated for CH25H loss, elicited angiostatic effects (alone or combined with sunitinib),
54 ffects at low therapeutic concentrations but angiostatic effects at high concentrations that are reve
55  In addition, the MIG chemokine also induced angiostatic effects in the tumor vasculature.
56                         We conclude that the angiostatic effects of endorepellin in vivo are mediated
57               This knowledge of the specific angiostatic effects of IL-4 may help optimize target-ori
58 211377, but pronounced anti-inflammatory and angiostatic effects were achieved by adding the EP1 anta
59  reduces synovial tissue vascularization via angiostatic effects, mediates inhibition of angiogenesis
60                                              Angiostatic efficacy in the cornea is also observed when
61 osis can be attenuated by treatment with the angiostatic ELR(-) CXC chemokine, CXCL11.
62                                          The angiostatic ELR- chemokines were expressed at high level
63 creased expression of the interferon-induced angiostatic ELR- CXC chemokines is a feature of juvenile
64 ng the immune microenvironment, inflammatory/angiostatic factor expression, angiogenic factor express
65 tic repressor of multiple pro-angiogenic and angiostatic factor genes in cardiomyocytes.
66 mor-derived IP-10 is an important endogenous angiostatic factor in NSCLC.
67                 Here we identify Cxcl9 as an angiostatic factor secreted by osteoblasts in the bone m
68 ly described angiostatic factor, as a potent angiostatic factor that regulates non-small cell lung ca
69  now report that IP-10, a recently described angiostatic factor, as a potent angiostatic factor that
70 ht to determine the relationship of a potent angiostatic factor, endostatin (ES), with disease severi
71                         Endostatin, a potent angiostatic factor, was expressed in mouse muscle and se
72  Therefore, we hypothesized that circulating angiostatic factors could be linked to outcomes and repr
73 sity by exposure to different angiogenic and angiostatic factors demonstrated the utility of this sys
74 d concerted expression of pro-angiogenic and angiostatic factors needed to produce functional microva
75  Inhibition of angiogenesis by production of angiostatic factors should be a viable approach for canc
76 ilar natural proteolytic fragment are potent angiostatic factors that act through the vascular endoth
77 a dual and opposing system of angiogenic and angiostatic factors.
78  cytokine that also stimulates production of angiostatic factors.
79 for a novel downstream signaling axis for an angiostatic fragment and for the key components involved
80 ve identified a new role for this endogenous angiostatic fragment in inducing autophagy through a VEG
81  receptor antagonism could operate for other angiostatic fragments.
82  unraveled a mechanistic explanation for the angiostatic functions attributed to ADAMTS1 and demonstr
83 t Peg3 induced the secretion of the powerful angiostatic glycoprotein Thrombospondin 1 independently
84 microvessel density in vivo and generates an angiostatic>angiogenic tumor microenvironment that retar
85 ts in the expression of angiogenic (IL-8) vs angiostatic (IFN-gamma-inducible protein (IP-10)) CXC ch
86 istinct immunovascular subtypes (immune-high/angiostatic [IH/AS], immune-mid/angio-mid [IM/AM], immun
87               Mini TrpRS is shown here to be angiostatic in a mammalian cell culture system, the chic
88 fic molecule designed as a substitute for an angiostatic inhibitory peptide.
89 which a subset of inflammatory cells secrete angiostatic ligands, which then contribute to a local at
90 tic effect of endorepellin and perhaps other angiostatic matrix proteins.
91 poor prognosis, especially when inflammatory/angiostatic milieu coexisted around tumor vessels.
92 lar protein thrombospondin (TSP)-1, a potent angiostatic molecule and crucial activator of transformi
93 in, the C-terminal domain of perlecan, is an angiostatic molecule that acts as a potent inducer of au
94 se studies demonstrate synergism between two angiostatic molecules and that antiangiogenic therapy ca
95                       Therapies that combine angiostatic molecules targeting multiple, distinct aspec
96 demonstrate synergistic effects of combining angiostatic molecules that target distinct aspects of th
97 ork that was skewed toward a proinflammatory angiostatic phenotype.
98   Tumor inhibition was presumably due to the angiostatic properties of anecortave acetate because the
99 ts ability to attract T cells as well as its angiostatic properties suggest that 6Ckine may be an eff
100                          M. miR-184 exhibits angiostatic properties via regulation of Akt and VEGF si
101 e other ligands of this receptor, 6Ckine has angiostatic properties.
102 tive kringle-containing fragments expressing angiostatic properties.
103 CXCL9) are T-cell chemoattractants that have angiostatic properties.
104  was inhibited when EPCs expressing a potent angiostatic protein were injected.
105 when compared with treatment with individual angiostatic protein.
106                      In the presence of both angiostatic proteins, endothelial cell proliferation was
107 bit VEGF-mediated angiogenesis and exert its angiostatic role in part via alphavbeta3 integrin.
108 epresents the first therapeutic effect of an angiostatic steroid in an animal model of neovascular re
109 tudy was designed to test the capacity of an angiostatic steroid, anecortave acetate, to inhibit reti
110            The inhibition of angiogenesis by angiostatic steroids has been demonstrated in a variety
111  the authors' laboratory have suggested that angiostatic steroids suppress the PA activity essential
112 w medical and surgical treatments, including angiostatic steroids, nonsteroidal inflammatory agents,
113                            Moreover, topical angiostatic strategies can lead to restoration of immune
114 ogenic factor that counterbalances canonical angiostatic TGF-beta signaling.
115                                              Angiostatic therapies designed to inhibit neovasculariza
116 determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retin
117      In contrast, treatment with combination angiostatic therapy significantly reduced compensatory u
118 umor vascular obliteration using combination angiostatic therapy was associated with reduced tumor ma
119 ing pathway may thus enhance the efficacy of angiostatic treatments for cancer and neovascular eye di

 
Page Top